SBIR/STTR Research Award

New method for detection of prion diseases

Award identifier d8f6c2c3a96de5d245b28e0b3daec5ccc0226a6a6361fbb896f23b2606f6d97aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,952

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOTRACES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose new methods for discovery of TSE biomarkers based on combing the MultiPhoton Detection (MPD) [1,2,3,4] technique with methods of proteomics [5,6,7,8], especially by applying MPD enhanced differential display of proteins (dd-PROT/MPD) and immunoassay (IA/MPD). Subsequently, the methods will be extended to MPD enhanced supersensitive protein chips (P-chips/MPD). These MPD enhanced techniques, developed by the group of Dr. A. K. Drukier, enable more sensitive and less expensive tests for correlating the levels of low abundance protein ("molecular switch") with TSE infections. These differentially displayed proteins will then be validated as TSE biomarkers. The primary objective of Phase I of this proposal is to discover differentially displayed proteins that are down regulated in TSE cases. A similar study was conducted a few years ago by Dr. M. Harrington, on CJD patients. This pioneering study was performed using silver stained 2D gels and revealed those differentially displayed proteins present at relatively high levels (1-10 fmole/ml) in CSF. Only one clearly up-regulated protein and a few possibly down-regulated proteins were discovered. The new tools of proteomics, such as dd-PROT/MPD and high-sensitivity mass spectroscopy, may allow detection and identification at the few attomole/ml level. Our study using proteomics methods sensitive to attomole/ml levels is expected to detect a few tens of differentially expressed proteins. Hopefully, some of them will also be present in blood to allow ante mortem TSE diagnosis. The identification of proteins via genomic information permits the synthesis of recombinant proteins and development of appropriate monoclonal antibodies (mAbs). If the importance of several TSE biomarkers is confirmed, we will develop dedicated supersensitive P-chips (P-chips/MPD) for quantifying up to 64 targeted differentially displayed proteins at 50 fg/ml. Thus, low cost ante mortem TSE detection methods will be developed.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.